Pazopanib and HDAC inhibitors interact to kill sarcoma cells

References

• Wilky BA, Meyer CF, Trent JC. Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol 2013; 25:373 - 8; http://dx.doi.org/10.1097/CCO.0b013e3283622d3a; PMID: 23666473
   PubMed Web of Science ®Google Scholar
• Rajendra R, Jones RL, Pollack SM. Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther 2013; 6:217 - 22; PMID: 23524973
   PubMed Web of Science ®Google Scholar
• Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs 2012; 21:451 - 72; http://dx.doi.org/10.1517/13543784.2012.661715; PMID: 22339615
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis 2010; 13:1 - 14; http://dx.doi.org/10.1007/s10456-009-9160-6; PMID: 20012482
   PubMed Web of Science ®Google Scholar
• Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 2010; 9:2220 - 31; http://dx.doi.org/10.1158/1535-7163.MCT-10-0274; PMID: 20682655
   PubMed Web of Science ®Google Scholar
• Gril B, Palmieri D, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Andreu Z, Masana D, Fernández P, Steeg PS, et al. Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol 2013; 182:2368 - 79; http://dx.doi.org/10.1016/j.ajpath.2013.02.043; PMID: 23583652
   PubMed Web of Science ®Google Scholar
• Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol 2013; 84:562 - 71; http://dx.doi.org/10.1124/mol.113.088005; PMID: 23877009
   PubMed Web of Science ®Google Scholar
• Ranieri G, Mammì M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M, De Sarro G. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol 2013; In press PMID: 24041629
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Verzoni E, De Braud F, Procopio G. First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile. Cancer Biol Ther 2014; 15:19 - 21; http://dx.doi.org/10.4161/cbt.27150; PMID: 24253418
   PubMed Web of Science ®Google Scholar
• Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 2011; 71:4955 - 67; http://dx.doi.org/10.1158/0008-5472.CAN-11-0898; PMID: 21622715
   PubMed Web of Science ®Google Scholar
• Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonfili L, Eleuteri AM, Mozzicafreddo M, Burattini L, et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 2013; 109:1040 - 50; http://dx.doi.org/10.1038/bjc.2013.420; PMID: 23887605
   PubMed Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J Jr.. Valproic acid as anti-cancer drug. Curr Pharm Des 2007; 13:3378 - 93; http://dx.doi.org/10.2174/138161207782360528; PMID: 18045192
   PubMed Web of Science ®Google Scholar
• Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011; 67:175 - 95; PMID: 21141730
   PubMedGoogle Scholar
• Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One 2012; 7:e52753; http://dx.doi.org/10.1371/journal.pone.0052753; PMID: 23300762
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 2013; 52:118 - 33; http://dx.doi.org/10.1002/mc.21835; PMID: 22086447
   PubMed Web of Science ®Google Scholar
• Shubassi G, Robert T, Vanoli F, Minucci S, Foiani M. Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res 2012; 72:1332 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-11-3172; PMID: 22422989
   PubMed Web of Science ®Google Scholar
• Jeong SG, Ohn T, Kim SH, Cho GW. Valproic acid promotes neuronal differentiation by induction of neuroprogenitors in human bone-marrow mesenchymal stromal cells. Neurosci Lett 2013; 554:22 - 7; http://dx.doi.org/10.1016/j.neulet.2013.08.059; PMID: 24021810
   PubMed Web of Science ®Google Scholar
• Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 2013; 139:1507 - 14; http://dx.doi.org/10.1007/s00432-013-1465-6; PMID: 23824064
   PubMed Web of Science ®Google Scholar
• Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther 2013; 14:982 - 96; http://dx.doi.org/10.4161/cbt.26234; PMID: 24025251
   PubMed Web of Science ®Google Scholar